Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.
Coombes RC, Badman PD, Lozano-Kuehne JP, Liu X, Macpherson IR, Zubairi I, Baird RD, Rosenfeld N, Garcia-Corbacho J, Cresti N, Plummer R, Armstrong A, Allerton R, Landers D, Nicholas H, McLellan L, Lim A, Mouliere F, Pardo OE, Ferguson V, Seckl MJ.
Coombes RC, et al. Among authors: pardo oe.
Nat Commun. 2023 Jan 17;14(1):260. doi: 10.1038/s41467-023-35969-4.
Nat Commun. 2023.
PMID: 36650166
Free PMC article.
No abstract available.